Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH budget

This article was originally published in The Gray Sheet

Executive Summary

Senate Appropriations Committee votes June 22 to report the fiscal year 2007 appropriations bill for the "Department of Agriculture, Rural Development, Food & Drug Administration, and Related Agencies" to the full Senate. As passed by the committee, the bill provides $229.2 mil. for CDRH, just $100,000 less than the President's budget request. In May, the House passed a version of the bill which shaved $476,000 off the President's request (1"The Gray Sheet" May 29, 2006, In Brief). Both versions of the budget are sufficient to enable continuation of the medical device user fee program...

You may also be interested in...



CDRH budget

House votes 378 to 46 in favor of proposed Center for Devices & Radiological Health fiscal 2007 budget of $228.8 mil. on May 23 as part of the "Agriculture, Rural Development, Food & Drug Administration, and Related Agencies Appropriations Act, 2007." Despite shaving $476,000 off the President's request, the figure passed is still sufficient to enable the MDUFMA user fee program, FDA says. The bill will be reconciled with upcoming legislation in the Senate...

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel